Who Buys Paracetamol from India — 2197 Importers Behind a $357.3M Market

The importers of Paracetamol from India can be categorized into several key segments:

1. Distributors: These entities purchase large quantities of Paracetamol to supply to various retailers, pharmacies, and healthcare providers. Their buying behavior is characterized by bulk purchasing to leverage economies of scale, ensuring a steady supply chain to meet market demand.

2. Hospital Groups: Hospitals and healthcare institutions procure Paracetamol directly for patient care. Their purchasing decisions are driven by the need for consistent quality, compliance with regulatory standards, and cost-effectiveness to manage healthcare budgets efficiently.

3. Retail Chains: Pharmacy and supermarket chains import Paracetamol to stock their shelves for consumer purchase. They focus on product availability, brand reputation, and competitive pricing to attract and retain customers.

4. Government Procurement Agencies: Organizations like UNICEF and the Global Fund procure Paracetamol for public health initiatives. Their buying behavior emphasizes large-scale purchases, stringent quality control, and adherence to international health standards to support healthcare programs in various regions.

5. Re-exporters: These buyers import Paracetamol with the intention of exporting it to other markets. They seek cost-effective sourcing to maximize profit margins while ensuring compliance with the regulatory requirements of both the importing and destination countries.

6. Contract Manufacturers: Companies that manufacture pharmaceutical products on behalf of other brands may import Paracetamol as an active pharmaceutical ingredient (API). Their purchasing decisions are influenced by the need for high-quality raw materials, reliable supply chains, and cost considerations to fulfill contractual obligations efficiently.

United Kingdom

1. Drug Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).

2. Import Registration Process: Importers must hold a Wholesale Dealer's License (WDA(H)) issued by the MHRA. The application involves demonstrating compliance with Good Distribution Practice (GDP) standards and providing details about the premises and personnel involved.

3. Estimated Timeline: The processing time for a WDA(H) application is approximately 90 days, subject to the completeness of the application and any required inspections.

4. Import Tariff for HS 3004: As of March 2026, the United Kingdom applies a 0% import tariff on pharmaceutical products classified under HS code 3004, aligning with its commitment to facilitate access to essential medicines.

Australia

1. Drug Regulatory Authority: Therapeutic Goods Administration (TGA).

2. Import Registration Process: Importers must register the product in the Australian Register of Therapeutic Goods (ARTG). This process includes submitting comprehensive data on product quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards.

3. Estimated Timeline: The registration process can take between 6 to 12 months, depending on the complexity of the application and the need for additional information or clarification.

4. Import Tariff for HS 3004: Australia imposes a 5% import tariff on pharmaceutical products under HS code 3004; however, certain products may be eligible for tariff concessions or exemptions under specific trade agreements.

South Africa

1. Drug Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).

2. Import Registration Process: Importers are required to obtain a license from SAHPRA, which involves submitting detailed product dossiers, evidence of GMP compliance, and adherence to labeling and packaging regulations.

3. Estimated Timeline: The licensing process typically takes 12 to 18 months, influenced by the completeness of the application and the scheduling of necessary inspections.

4. Import Tariff for HS 3004: South Africa applies a 0% import tariff on pharmaceutical products under HS code 3004, facilitating the importation of essential medicines.

Netherlands

1. Drug Regulatory Authority: Medicines Evaluation Board (MEB).

2. Import Registration Process: Importers must obtain a Marketing Authorization from the MEB, which requires submission of comprehensive data on product quality, safety, and efficacy, as well as compliance with European Union GMP standards.

3. Estimated Timeline: The authorization process can take approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff for HS 3004: As a member of the European Union, the Netherlands applies a 0% import tariff on pharmaceutical products under HS code 3004, in line with EU regulations.

France

1. Drug Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).

2. Import Registration Process: Importers are required to obtain a Marketing Authorization from ANSM, involving the submission of detailed product information, clinical data, and evidence of GMP compliance.

3. Estimated Timeline: The authorization process typically takes 180 to 210 days, depending on the complexity of the application and any additional information required.

4. Import Tariff for HS 3004: France, as part of the European Union, applies a 0% import tariff on pharmaceutical products under HS code 3004, facilitating the importation of essential medicines.

The demand for Paracetamol in importing countries is driven by several key factors:

1. Disease Prevalence: Paracetamol is widely used for the treatment of pain and fever associated with various illnesses, including influenza, common colds, and other viral infections. Seasonal outbreaks and the prevalence of such conditions significantly increase the demand for Paracetamol.

2. Government Healthcare Programs: Many countries have implemented healthcare programs that provide essential medicines to the population. Paracetamol, being a cost-effective and widely accepted analgesic and antipyretic, is often included in these programs, leading to substantial procurement by government agencies.

3. Universal Health Coverage Expansion: The global push towards universal health coverage has led to increased access to essential medicines. Countries expanding their healthcare coverage ensure that medications like Paracetamol are readily available to their populations, thereby driving import volumes.

4. Tender Procurement: Public and private healthcare institutions often procure medicines through tender processes to ensure cost-effectiveness and supply reliability. Paracetamol, due to its essential status, is frequently included in such tenders, leading to bulk purchasing and increased importation.

Recent data indicates a steady growth in the global demand for Paracetamol, with emerging markets showing significant increases due to improved healthcare infrastructure and access. Additionally, the ongoing efforts to manage and treat common illnesses effectively continue to position Paracetamol as a critical component in healthcare systems worldwide.

The importers of Paracetamol from India can be categorized into several key segments:

1. Distributors: These entities purchase large quantities of Paracetamol to supply to various retailers, pharmacies, and healthcare providers. Their buying behavior is characterized by bulk purchasing to leverage economies of scale, ensuring a steady supply chain to meet market demand.

2. Hospital Groups: Hospitals and healthcare institutions procure Paracetamol directly for patient care. Their purchasing decisions are driven by the need for consistent quality, compliance with regulatory standards, and cost-effectiveness to manage healthcare budgets efficiently.

3. Retail Chains: Pharmacy and supermarket chains import Paracetamol to stock their shelves for consumer purchase. They focus on product availability, brand reputation, and competitive pricing to attract and retain customers.

4. Government Procurement Agencies: Organizations like UNICEF and the Global Fund procure Paracetamol for public health initiatives. Their buying behavior emphasizes large-scale purchases, stringent quality control, and adherence to international health standards to support healthcare programs in various regions.

5. Re-exporters: These buyers import Paracetamol with the intention of exporting it to other markets. They seek cost-effective sourcing to maximize profit margins while ensuring compliance with the regulatory requirements of both the importing and destination countries.

6. Contract Manufacturers: Companies that manufacture pharmaceutical products on behalf of other brands may import Paracetamol as an active pharmaceutical ingredient (API). Their purchasing decisions are influenced by the need for high-quality raw materials, reliable supply chains, and cost considerations to fulfill contractual obligations efficiently.

United Kingdom

1. Drug Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).

2. Import Registration Process: Importers must hold a Wholesale Dealer's License (WDA(H)) issued by the MHRA. The application involves demonstrating compliance with Good Distribution Practice (GDP) standards and providing details about the premises and personnel involved.

3. Estimated Timeline: The processing time for a WDA(H) application is approximately 90 days, subject to the completeness of the application and any required inspections.

4. Import Tariff for HS 3004: As of March 2026, the United Kingdom applies a 0% import tariff on pharmaceutical products classified under HS code 3004, aligning with its commitment to facilitate access to essential medicines.

Australia

1. Drug Regulatory Authority: Therapeutic Goods Administration (TGA).

2. Import Registration Process: Importers must register the product in the Australian Register of Therapeutic Goods (ARTG). This process includes submitting comprehensive data on product quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards.

3. Estimated Timeline: The registration process can take between 6 to 12 months, depending on the complexity of the application and the need for additional information or clarification.

4. Import Tariff for HS 3004: Australia imposes a 5% import tariff on pharmaceutical products under HS code 3004; however, certain products may be eligible for tariff concessions or exemptions under specific trade agreements.

South Africa

1. Drug Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).

2. Import Registration Process: Importers are required to obtain a license from SAHPRA, which involves submitting detailed product dossiers, evidence of GMP compliance, and adherence to labeling and packaging regulations.

3. Estimated Timeline: The licensing process typically takes 12 to 18 months, influenced by the completeness of the application and the scheduling of necessary inspections.

4. Import Tariff for HS 3004: South Africa applies a 0% import tariff on pharmaceutical products under HS code 3004, facilitating the importation of essential medicines.

Netherlands

1. Drug Regulatory Authority: Medicines Evaluation Board (MEB).

2. Import Registration Process: Importers must obtain a Marketing Authorization from the MEB, which requires submission of comprehensive data on product quality, safety, and efficacy, as well as compliance with European Union GMP standards.

3. Estimated Timeline: The authorization process can take approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff for HS 3004: As a member of the European Union, the Netherlands applies a 0% import tariff on pharmaceutical products under HS code 3004, in line with EU regulations.

France

1. Drug Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).

2. Import Registration Process: Importers are required to obtain a Marketing Authorization from ANSM, involving the submission of detailed product information, clinical data, and evidence of GMP compliance.

3. Estimated Timeline: The authorization process typically takes 180 to 210 days, depending on the complexity of the application and any additional information required.

4. Import Tariff for HS 3004: France, as part of the European Union, applies a 0% import tariff on pharmaceutical products under HS code 3004, facilitating the importation of essential medicines.

The demand for Paracetamol in importing countries is driven by several key factors:

1. Disease Prevalence: Paracetamol is widely used for the treatment of pain and fever associated with various illnesses, including influenza, common colds, and other viral infections. Seasonal outbreaks and the prevalence of such conditions significantly increase the demand for Paracetamol.

2. Government Healthcare Programs: Many countries have implemented healthcare programs that provide essential medicines to the population. Paracetamol, being a cost-effective and widely accepted analgesic and antipyretic, is often included in these programs, leading to substantial procurement by government agencies.

3. Universal Health Coverage Expansion: The global push towards universal health coverage has led to increased access to essential medicines. Countries expanding their healthcare coverage ensure that medications like Paracetamol are readily available to their populations, thereby driving import volumes.

4. Tender Procurement: Public and private healthcare institutions often procure medicines through tender processes to ensure cost-effectiveness and supply reliability. Paracetamol, due to its essential status, is frequently included in such tenders, leading to bulk purchasing and increased importation.

Recent data indicates a steady growth in the global demand for Paracetamol, with emerging markets showing significant increases due to improved healthcare infrastructure and access. Additionally, the ongoing efforts to manage and treat common illnesses effectively continue to position Paracetamol as a critical component in healthcare systems worldwide.